Core Insights - Earth Science Tech, Inc. (ETST) has qualified for and been listed on the newly launched OTCID tier of the OTC Markets, reflecting its commitment to enhanced disclosure and compliance standards [1][2] - The CEO, Giorgio R. Saumat, highlighted the company's significant turnaround over the past two years and expressed optimism about future growth and increased investor confidence due to this new designation [3] Company Overview - ETST operates as a strategic holding company focused on acquiring and optimizing high-potential businesses, with current operations in compounding pharmaceuticals, telemedicine, and real estate development through various subsidiaries [4] - The company's subsidiaries include RxCompoundStore.com, Peaks Curative, Avenvi, Mister Meds, and others, each specializing in different aspects of healthcare and real estate [4][10] Subsidiary Highlights - **RxCompoundStore.com**: A fully licensed compounding pharmacy serving multiple states and actively pursuing licensure in remaining U.S. states [5] - **Mister Meds**: A compounding pharmacy in Texas that received full licensure in March 2025 and is expanding its service area [6] - **Peaks Curative**: A telemedicine platform offering consultations for compounded medications and recently expanded into the veterinary market [7] - **Las Villas Health Care**: A healthcare facility focused on the Spanish-speaking community, providing specialized health services [8] - **Avenvi**: A diversified real estate company managing development and financing activities, overseeing a $5 million share repurchase program [10] - **Earth Science Foundation**: A nonprofit organization supporting individuals with financial needs for prescription costs [11]

Core Insights - GRI Bio, Inc. has completed patient enrollment for its Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) [1][2] - The company is on track to report 6-week interim biomarker results in July 2025, with topline data expected in Q3 2025 [1][6] - GRI-0621 is being developed as a novel oral therapeutic targeting Natural Killer T (NKT) cells, which play a critical role in inflammatory and fibrotic diseases [8] Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on treating inflammatory, fibrotic, and autoimmune diseases through NKT cell modulation [8] - The lead program, GRI-0621, is an inhibitor of iNKT cell activity aimed at addressing the unmet needs in IPF treatment [8] Study Design and Results - The Phase 2a study is a randomized, double-blind, placebo-controlled trial enrolling approximately 35 subjects, with a 2:1 randomization for GRI-0621 (4.5mg) versus placebo [3] - Primary endpoint focuses on safety and tolerability after 12 weeks, while secondary endpoints include changes in serum biomarkers and pharmacokinetics [3] - Interim safety results from the first 12 and 24 patients indicated that GRI-0621 is safe and well-tolerated, with no significant changes in lipid levels observed [4][5] Future Expectations - The company anticipates reporting 6-week interim biomarker data in July 2025, followed by topline results in Q3 2025 [6]

Company Overview - Wearable Devices Ltd. is a technology growth company specializing in AI-powered touchless sensing wearable devices [6] - The company offers products for both consumer and business markets, including the Mudra Link and Mudra Band for B2C consumers, and the Mudra Development Kit for B2B enterprises [4][6] - The flagship product, Mudra Link, is a neural input wristband that enables hands-free, gesture-based control of digital devices using neural signals [3][6] Product Highlights - Mudra Link began shipping earlier this year and is compatible with multiple platforms including Android, iOS, Windows, and macOS, as well as leading AR glasses [3] - The product has received a CES 2025 Innovation Award and has been praised for its intuitive interface and low-latency performance [3] - The Mudra Band integrates stylish design with advanced AI to empower consumers, while the enterprise solutions provide tools for immersive experiences [6] Industry Context - XR Fair Tokyo is a leading B2B exhibition focused on virtual reality, augmented reality, mixed reality, and the broader metaverse ecosystem [2] - The event serves as a platform for companies to showcase innovations across various industries, including entertainment, manufacturing, and education [2] - The growing adoption of gesture-based controls in smart glasses and face-worn devices is highlighted as a trend in the industry [5] Upcoming Events - Wearable Devices will exhibit at the Fifth XR Fair Tokyo from July 2 to July 4, 2025, at the Tokyo Big Sight convention center [1] - The company aims to showcase how Mudra enables seamless, hands-free interaction across AR use cases during this event [5]

Core Insights - Flux Power Holdings, Inc. has received a significant purchase order from a major U.S. airline for 120 units of its G80-420 lithium-ion battery packs, valued at over $2 million, to be delivered throughout 2025 [1][2][3] - The order signifies a shift towards data-enabled, zero-emission equipment in airport operations, despite challenges from trade policies and economic pressures [2][3] - The G80-420 battery packs are designed for high-intensity ground support equipment (GSE) applications, featuring modular architecture for fast service and embedded telematics for real-time insights [4][5] Company Overview - Flux Power specializes in advanced lithium-ion energy storage solutions for various sectors, including airport ground support equipment, offering a more environmentally friendly alternative to traditional energy sources [7] - The company emphasizes the integration of intelligence, adaptability, and serviceability in its energy platform, aiming to enhance operational efficiency and sustainability for its customers [5][7] Partnership and Collaboration - The order was secured through collaboration with Averest, a key player in the GSE space, which has a strong understanding of airport fleet challenges [3][4] - Averest focuses on providing customized electric power solutions for the aviation industry, contributing to the transition towards cleaner energy systems [6]

Core Insights - ReShape Lifesciences announced the issuance of U.S. Patent 12,350,179 for an intragastric device, enhancing its intellectual property portfolio [1][2] - The patent covers a swallowable capsule with a self-sealing fill valve and a degradable release valve, designed for natural excretion after deflation [1] - The patent protection extends to at least January 2031, potentially longer with a Patent Term Extension [1] Intellectual Property Development - The company has secured over 50 patents related to its intragastric balloon technology since its initial filing in 2011, contributing to a total of over 160 issued and pending patents [2] - This robust patent portfolio positions the company to defend its competitive edge and support its innovation pipeline [2] Company Overview - ReShape Lifesciences specializes in weight loss and metabolic health solutions, offering products like the FDA-approved Lap-Band systems and the non-surgical Obalon balloon technology [3] - The company aims to provide integrated solutions for managing obesity and metabolic diseases [3] Recent Transactions - ReShape has entered into an asset purchase agreement with Biorad Medisys, agreeing to sell substantially all of its assets, including the Lap-Band and Obalon systems [4]

SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company’s Series H Convertible Preferred Stock (“Preferred Stock”), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Company at an ex ...

Core Insights - Snail, Inc. has launched two new indie titles, "Robots at Midnight" and "Zombie Rollerz: The Last Ship," marking a strategic expansion into diverse game demographics [1][4] Group 1: Game Launches - "Robots at Midnight" targets younger Gen Z and Gen Alpha players, designed as an accessible entry-level Souls-like game to lower the barrier for engagement [2] - "Zombie Rollerz: The Last Ship" is a sequel that combines roguelite mechanics with tower defense strategy, building on the success of its predecessor which has over 10 million downloads [3] Group 2: Strategic Focus - The launches reflect Snail Games' commitment to portfolio diversification, aiming to engage underserved player segments and expand market presence [4] - The company is investing in long-term strategies to build brand loyalty among the next generation of gamers, particularly as Gen Alpha is projected to be highly digitally fluent and commercially influential [2][4]

New law goes into effect on July 1 authorizing Florida physicians to provide stem cell therapies to their patients for orthopedics, wound care, and pain management FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today hailed a new Florida law taking effect today that opens the door to physicians' use of investigational stem cell therapies in the state in orthopedics, wound care, and pain manag ...

Important Milestone Clears the Way for Millions of Medicare Beneficiaries with Sleep Apnea to Access Vivos’ Patented and FDA-Cleared Oral Appliance TreatmentLITTLETON, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced that its VidaSleep™ oral appliance, featuring Vivos’ patented and U.S. Food and Drug Administration (FD ...

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- eToro Group Ltd. ("eToro", or the "Company") (NASDAQ: ETOR), the trading and investing platform, today announced the closing of a new three year $250 million senior unsecured revolving credit facility ("the Facility"). eToro is the trading and investing platform that empowers you to invest, share and learn. We were founded in 2007 with the vision of a world where everyone can trade and invest in a simple and transparent way. Today we have 40 million registered use ...